Trial
NCT01166724
Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression-
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
The Cleveland Clinic
Collaborators
Pfizer
Condition
Kidney Transplant
Intervention
Sirolimus
Why stopped
Collaborator stopped study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-06-07